# US 2022/0031833 A1 · Inactivated whole-virus influenza vaccine and method for preparing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031833 A1
- Document ID: US20220031833A1
- Status: Published application
- Kind: A1
- Application number: 17/279,898
- Filed: 2019-09-26
- Published: 2022-02-03
- Earliest claimed: 2018-09-26
- Assignees: Denka Company Limited; National University Corporation Kumamoto University
- Applicants: Denka Company Limited; National University Corporation Kumamoto University
- Inventors: Ryotaro MITSUMATA; Shogo MISUMI; Naoki KISHIMOTO; Takuma GOTANDA; Nagisa NAKATA
- Web page: https://patentgrep.com/patent/US20220031833A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/16: for influenza or rhinoviruses
- C12N 15/1131: {against viruses}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.

## Claims

### Claim 1

A method for preparing an inactivated whole-virus influenza vaccine using an embryonated chicken egg technique, the method comprising:
subjecting a virus solution, comprising whole influenza virus particles collected from embryonated chicken eggs, to a hypotonic treatment.

### Claim 2 (depends on 1)

The method of claim 1, wherein the hypotonic treatment comprises exposing the virus solution to a hypotonic solution.

### Claim 3 (depends on 2)

The method of claim 2, wherein the hypotonic solution is an aqueous solution of 160 mOsm/kg or less.

### Claim 4 (depends on 1)

The method of claim 1, wherein the virus solution which has been inactivated is subjected to the hypotonic treatment.

### Claim 5 (depends on 1)

An inactivated whole-virus influenza vaccine, prepared by the method of claim 1.

### Claim 6

An inactivated whole-virus influenza vaccine, prepared by an embryonated chicken egg technique, wherein extracellular vesicle components derived from embryonated chicken eggs are reduced.

### Claim 7 (depends on 2)

The method of claim 2, wherein the hypotonic solution is an aqueous solution of 110 mOsm/kg or less.